Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Multiple myeloma science from EHA 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 603
Rating:

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Prof Mohamad Mohty speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about what is being discussed in multiple myeloma at EHA 2019.

He believes that the use of monoclonal antibodies have been a real highlight from this meeting and names the CASSIOPEIA and COLUMBA trials as showing important data.

Prof Mohty also discusses bispecific antibodies, with a study showing a very high rate of response from treatment with AMG 420.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation